Watson Confirms Velcade® Patent Challenge

                  Watson Confirms Velcade® Patent Challenge

PR Newswire

PARSIPPANY, N.J., Dec. 28, 2012

PARSIPPANY, N.J., Dec.28, 2012 /PRNewswire/ --Watson Pharmaceuticals, Inc.
(NYSE: WPI) today confirmed that Actavis, Inc., which was acquired by Watson
in October, has filed an Abbreviated New Drug Application (ANDA) with the U.S.
Food and Drug Administration (FDA) seeking approval to market bortezomib.
Actavis' ANDA product is a generic version of Millennium Pharmaceuticals'
Velcade ^ ® (bortezomib), which is a proteasome inhibitor, for intravenous or
subcutaneous administration, approved for the treatment of patients with
multiple myeloma and patients with mantle cell lymphoma who have received at
least one prior therapy.

Millennium filed suit against Actavis on December 21, 2012, in the U.S.
District Court for the District of Delaware seeking to prevent Actavis from
commercializing its ANDA product prior to the expiration of certain U.S.
patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act,
resulting in a stay of finalFDAapproval of Actavis' ANDA for up to 30 months
from the date the plaintiffs received notice of Actavis' ANDA filing or until
final resolution of the matter before the court, whichever occurs sooner,
subject to any other exclusivities.

For the 12 months ending October 31, 2012, Velcade^® had total U.S. sales of
approximately $740 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals,Inc. (NYSE: WPI) is a global, integrated specialty
pharmaceutical company focused on developing, manufacturing and distributing
generic, brand and biosimilar products. The Company has global and U.S.
headquarters in Parsippany, New Jersey, USA, and international headquarters in
Zug, Switzerland.

Watson is the world's third-largest generics prescription drug manufacturer,
with more than 750 products marketed globally through operations in more than
60 countries. Watson's global branded pharmaceutical business develops and
markets products principally in Urology and Women's Health, and iscommitted
to developing and marketing biosimilars products in Women's Health, Oncology
and other therapeutic categories. In addition, Watson is the fourth-largest
U.S. generic pharmaceutical product distributor through its Anda, Inc.
business, and also develops and out-licenses generic pharmaceutical products
outside of the U.S. through its Medis third-party business. Watson has
announced that it will adopt a new global name – Actavis – effective in 2013.

For press release and other company information, visit Watson Pharmaceuticals'
Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts
are forward-looking statements that reflect Watson's current perspective of
existing information as of the date of this release. It is important to note
that Watson's goals and expectations are not predictions of actual
performance. Actual results may differ materially from Watson's current
expectations depending upon a number of factors, risks and uncertainties
affecting Watson's business. These factors include, among others, the impact
of competitive products and pricing; the timing and success of product
launches; difficulties or delays in manufacturing; the availability and
pricing of third party sourced products and materials; successful compliance
with FDA and other governmental regulations applicable to Watson and its third
party manufacturers' facilities, products and/or businesses; changes in the
laws and regulations, including Medicare and Medicaid, affecting among other
things, pricing and reimbursement of pharmaceutical products; and such other
risks and uncertainties detailed in Watson's periodic public filings with the
Securities and Exchange Commission, including but not limited to Watson's
Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 and
Watson's Annual Report on Form 10-K for the year ended December 31, 2011.
Except as expressly required by law, Watson disclaims any intent or obligation
to update these forward-looking statements.

Velcade^® is a registered trademark of Millennium Pharmaceuticals, Inc.

CONTACTS: Investors:
          Lisa DeFrancesco
          (862) 261-7152
          Charlie Mayr
          (862) 261-8030


SOURCE Watson Pharmaceuticals, Inc.

Website: http://www.watson.com
Press spacebar to pause and continue. Press esc to stop.